Table IV.

Toxicity grades of patients in the two groups from the matched dataset.

	No. of patients (%)
	Chemotherapy-bevacizumab (n=38)		Chemotherapy alone (n=38)
Toxicity	Grade 1/2	Grade ≥3	Grade 1/2	Grade ≥3
Hematological toxicity
Leukopenia	14 (36.8)	5 (13.2)	11 (28.9)	4 (10.5)
Neutropenia	11 (28.9)	3 (7.9)	9 (23.7)	4 (10.5)
Anemia	15 (39.5)	0 (0.0)	12 (31.6)	1 (2.6)
Thrombocytopenia	6 (15.8)	1 (2.6)	7 (18.4)	2 (5.3)
Non-hematological toxicity
Increased ALT or AST	15 (39.5)	2 (5.3)	13 (34.2)	1 (2.6)
Fatigue	14 (36.8)	2 (5.3)	12 (31.6)	0 (0.0)
Nausea	12 (31.6)	0 (0.0)	15 (39.5)	1 (2.6)
Vomiting	7 (18.4)	0 (0.0)	7 (18.4)	1 (2.6)
Rash	4 (10.5)	0 (0.0)	3 (7.9)	0 (0.0)
Joint or muscle pain	4 (10.5)	0 (0.0)	1 (2.6)	0 (0.0)
Hypertension	6 (15.8)	0 (0.0)	0 (0.0)	0 (0.0)
Bleeding	15 (39.5)	0 (0.0)	2 (5.3)	0 (0.0)
Proteinuria	4 (10.5)	0 (0.0)	0 (0.0)	0 (0.0)

ALT, alanine transaminase; AST, aspartate transaminase.